Eliquis And Opdivo Will Likely Continue To Drive Bristol-Myers Squibb's Earnings Growth

Bristol-Myers Squibb (NYSE:BMY) continues to see steady top line growth, primarily led by a ramp up in Opdivo and Eliquis' sales. The company's Q3 numbers were more or less in line with our estimates, led by a strong growth in these two drugs. Looking forward, we continue to believe that Opdivo...